trial · primary record
Elotuzumab
Myeloma
| Phase | Phase 1 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 24 |
| Primary completion | 2034-12-31 |
| Primary endpoint | Number of Participants Experiencing Dose Limiting Toxicity (DLT) |
| Registry ID | NCT06518551 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:47:54.241Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06518551
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.